Shire Newsroom: Media, News & Press Releases

shire map

Select a
Location

Shire Global

Europe

Americas

Asia Pacific

11/16/2018
Rule 2.9 announcement
11/16/2018
Shire Announces New HELP Study(TM) Data for Lanadelumab in Hereditary Angioedema (HAE) at 2018 ACAAI Annual Scientific Meeting
11/14/2018
Rule 2.9 announcement
11/13/2018
U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide [rDNA origin]) for Children with Short Bowel Syndrome
11/12/2018
Rule 2.9 announcement
11/12/2018
Publication of Scheme Document
11/09/2018
Rule 2.9 announcement
11/07/2018
Rule 2.9 announcement
11/06/2018
Rule 2.9 announcement
11/02/2018
Rule 2.9 announcement
11/01/2018
Director/PDMR Shareholding
11/01/2018
Shire Delivers Product Sales Growth of 6% and Continues to Execute Against Key Priorities in Q3 2018
11/01/2018
Total Voting Rights
11/01/2018
Rule 2.9 announcement
11/01/2018
Form 8 (DD) – Flemming Ornskov
10/30/2018
Rule 2.9 announcement
10/26/2018
Rule 2.9 announcement
10/25/2018
Shire Files Submission for U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia
10/25/2018
Rule 2.9 announcement
10/24/2018
Rule 2.9 announcement
10/23/2018
Rule 2.9 announcement
10/22/2018
Rule 2.9 announcement
10/19/2018
CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks
10/19/2018
Rule 2.9 announcement
10/18/2018
FDA Advisory Committee Recommends Approval of Shire’s Prucalopride (SHP555) for Chronic Idiopathic Constipation

LOAD MORE

Media Contacts

External Communications

Katie Joyce
Communications & Public Affairs
KJoyce@shire.com

For All International Inquiries

Deborah Hibbett
Communications & Public Affairs
dhibbett@shire.com

Kirsty Langton
Communications & Public Affairs
kirsty.langton@shire.com

In This Section

medialibrary

Media Library

Learn more

socialmedia

Social Media

Learn more

Committed To Responsibility

We make decisions that put patients first.

Subscribe to Shire News Alerts

Sign up for and select the type of alerts you would like to receive by email.

TOP

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE

CONTINUE DISAGREE